MMJ BioPharma’s noble pursuit of scientific advancement has been met with a series of inexplicable roadblocks and bureaucratic hurdles erected by the DEA. In 2018, the company dutifully applied for the necessary licenses to cultivate marijuana for research and development purposes, eagerly anticipating the opportunity to commence clinical trials that could yield life-changing treatments. Yet, despite meticulously following the DEA’s convoluted application process, MMJ BioPharma found itself trapped in a seemingly endless cycle of delays, obfuscation, and stonewalling.
The Dispensary Fulton offering huge discounts on top brands all month long. The post Save…
Republicans seek to put Ohioans back in jail for conduct voters already approved. The post…
The proposal to exclude medical marijuana from workers’ compensation coverage in California raises important concerns…
ILGM is hitting the road in their revamped Airstream Bambi for the Home Grow Tour…
Meet the music and cannabis pioneer behind the Upper East Side's hottest new dispensary. The…
Let's dive into how this iconic marijuana mecca rose to prominence, flourished during the golden…